Medix Biochemica Strengthens In-Vitro Diagnostics Offerings With CANDOR Bioscience Acquisition

Medix Biochemica is a global leader providing essential materials for in vitro diagnostics (IVD). The company has announced the acquisition of CANDOR Bioscience GmbH, a German company known for creating high-quality immunoassay solutions. This acquisition supports Medix Biochemica in expanding its offerings of raw materials and boosts its ability to support test developers in creating better immunoassays. CANDOR’s operations will continue in Wangen im Allgäu, Germany, after the acquisition.

Steve Ferguson, CEO of Medix Biochemica, commented, “We are delighted to welcome CANDOR into the Medix Biochemica family. The partnership with CANDOR strengthens Medix Biochemica’s ability to support our customer base by adding complementary expertise in immunoassay development and broadening our offering of critical IVD raw materials with a leading portfolio of premium blockers and stabilisers. Together, we will continue to provide the highest quality raw materials that enable diagnostic innovation, and we look forward to a successful collaboration with the CANDOR team.” 

CANDOR Bioscience, established in 2004 by Dr. Tobias Polifke and Dr. Peter Rauch, offers a wide range of products for immunoassays, such as blockers for interference and HAMA, surface blockers, stabilisers, and buffer solutions. These products help immunoassay manufacturers achieve more reliable test results, simplify the design process, and save time in testing.

“Joining forces with Medix Biochemica is an exciting milestone for CANDOR. We are proud of our legacy in providing differentiated, high-performance solutions for immunoassay development, and we share Medix Biochemica’s commitment to quality and innovation. By combining our capabilities and offerings, we will be better positioned to support the evolving needs of our customers. Medix Biochemica’s products, including antibodies and quality control materials, perfectly complement our solutions, enhancing the value we offer to partners in the IVD industry,” said Dr. Tobias Polifke and Dr. Peter Rauch, co-founders and Managing Directors of CANDOR Bioscience.